Skip survey header

HCV Management in Family Practice Pre-Survey

We would appreciate your cooperation in answering the following survey BEFORE the program begins. Please circle the optimal answer to the following questions. NOTE: All individual responses will remain confidential, while overall results may be shared and reported. Thank you for your time.

Any information you provide will be used by Med-IQ, Inc. in a manner consistent with the Privacy Notice and may be shared with third-party vendors. By submitting responses, you accept our Terms of Use and Privacy Notice.
Degree/Profession: *This question is required.
Specialty: *This question is required.
Type of practice: *This question is required.
2. How confident are you in your ability to plan appropriate HCV treatment? *This question is required.
3. While receiving direct-acting antiviral (DAA) treatment, patients should visit the office every _______ so clinicians can assess adherence to therapy, discuss any side effects, review appropriate laboratory results, and provide patient support.    *This question is required.
4. According to current guidelines, DAA treatment is recommended for all patients with chronic HCV infection EXCEPT perhaps in those with which of the following characteristics?    *This question is required.
5. Patients who complete DAA therapy and achieve a sustained virologic response (SVR) but have stage F3 or F4 fibrosis should undergo surveillance for HCC with ultrasound examination:   *This question is required.
6. AH has chronic HCV infection and compensated cirrhosis. She explains that she “hates” taking medicine for any extended period of time and is concerned that she will not be able to successfully complete therapy. Considering AH’s treatment concerns, which of the following DAA therapies would you recommend for her? *This question is required.
7. A 42-year-old man who claims he has never been tested for HCV was recently screened. His results show that he is HCV Ab positive, and his HCV RNA is 450,000 IU/L. He has no clinical signs of decompensation, and further work-up reveals that he has HCV genotype 1a, a platelet count of 90,000/mcL, FibroScan (transient elastography) measurement of 14 kPa, and a FIB-4 score of 3.3. He takes rosuvastatin to control hyperlipidemia. Which of the following care plans is optimal for this patient moving forward? *This question is required.